Pharmacokinetics cyclosporin A (Bioral) in kidney transplant recipients
Abstract
During the last years in clinical practice has used a few new drug formulations of cyclosporine A (CsA).The aim of this study was to describe pharmacokinetic properties of Cs microemulsion, bioral (Panimmune Bioral TM Panacea Biotech).We determined in 24 patients after kidney transplantation C0, Cmax, Tmax, AUC0-12, AUC0-4. These results suggests that bioral have the same FK properties that neoral.
About the Authors
F. S. Baranova
НИИ трансплантологии и искусственных органов МЗ РФ
Russian Federation
Russian Federation
J. F. Melukova
НИИ трансплантологии и искусственных органов МЗ РФ
Russian Federation
Russian Federation
L. K. Popova
НИИ трансплантологии и искусственных органов МЗ РФ
Russian Federation
Russian Federation
T. V. Korsakova
НИИ трансплантологии и искусственных органов МЗ РФ
Russian Federation
Russian Federation
O. N. Kotenko
НИИ трансплантологии и искусственных органов МЗ РФ
Russian Federation
Russian Federation
O. N. Rjevskaya
НИИ трансплантологии и искусственных органов МЗ РФ
Russian Federation
Russian Federation
N. V. Tarabarko
НИИ трансплантологии и искусственных органов МЗ РФ
Russian Federation
Russian Federation
Y. G. Moisuk
НИИ трансплантологии и искусственных органов МЗ РФ
Russian Federation
Russian Federation
References
1. Belitsky P. Neoral use in the renal Transplant recipient. Transplantation Proceedings. 2000; 32; 3A: 10S-19S.
2. Levy G. Introduction. Transplantation Proceedings. 2000; 32; 3A: 1S.
3. Mahalati K., Barry D. Kahan. Advancing the art of immunosuppression with the science of pharmacology. Current opinion in organ transplantation. 2000; 5; 3: 255.
4. Levy G.A. C2 monitoring strategy for optimizing cyclosporin immunosuppression from Neoral formulation. BioDrug. 2001; 15 (5): 279-290.
5. Singh S., Sharma D.R. A review of absorption characteristic of microemulsion cyclosporin product over the last 2 year in indian subject. J Indian Med Association. 1999; 97 (3): 114-117.
6. Singh S., Sharma D.R. Evaluation of kidney function and cyclosporin level in renal transplant recipient on Panimmune Bioral in post transplant period. J Indian Med Association. 1999 May; 97 (5): 204-205.
7. Amante A.S., Kahan B.D. Abbreviated AUC strategy for monitoring cyclosporin microemulsion therapy in the immediate posttransplant period. Transpl Proc. 1996; 28 (4): 2162-2163.
8. David O.J., Johnston A. Limited sampling strategy for estimation cyclosporin area under the concentration-time curve: review of current algoritm. Therapeutic Drug monitoring. 2001; 23 (2): 100-114.
9. Gaspari F., Anedda M.F., Signorini O., Romuzzi G., Perico N. Prediction of cyclosporine area under the curve using three-point sampling strategy after neoral administration. J Amer Soc Nephrol. 1997; 647-652.
10. Belitsky P., Dunn S., A.J., Johnston A., Levy G. Impact of Absorbtion Profiling on efficacy and safety of cyclosporin Therapy in transplant recipients. Clinical Pharmacokinetic. 2000; 39 (2).
11. Kahan B.D., Dunn J. et al. Reduced inter- and intrasubject variability in cyclosporin pharmacokinetics in renal transplant recipient treated with microemulsion formulation in conjuction with fasting, low fat meal, or high fat meals. Transplantation. 1995; 59: 505-11.
Review
For citations:
Baranova F.S., Melukova J.F., Popova L.K., Korsakova T.V., Kotenko O.N., Rjevskaya O.N., Tarabarko N.V., Moisuk Y.G. Pharmacokinetics cyclosporin A (Bioral) in kidney transplant recipients. Nephrology and Dialysis. 2001;3(4):451-453. (In Russ.)
Views:
8
Email this article 